Searchable abstracts of presentations at key conferences in endocrinology

ea0034p304 | Pituitary | SFEBES2014

Disordered sleep architecture is a common finding in acromegaly

Powlson Andrew S , Bala Laksha , Annamalai Anand K , Koulouri Olympia , Webb Alison , Moir Samantha , Shneerson John M , Gurnell Mark

Sleep disordered breathing (SDB), including obstructive sleep apnoea (OSA), is associated with excessive daytime somnolence, and impacts significantly on quality of life in affected individuals. It also predisposes to premature cardiovascular (hypertension, congestive cardiac failure, myocardial infarction, sudden death, and stroke) and metabolic (diabetes mellitus and dyslipidaemia) dysfunction.SDB is a well-recognised complication of acromegaly. In mos...

ea0025p309 | Steroids | SFEBES2011

Utility of basal DHEAS measurement in the detection of subclinical autonomous glucocorticoid hypersecretion in adrenal incidentaloma

Annamalai Anand K , Kandasamy Narayanan , Freeman Natalie , Venugopal Kuhan , Chia Jonathan , Shaw Ashley , Simpson Helen L , Halsall David , Gurnell Mark

Background: Adrenal incidentalomas (AI) are identified in 4–7% of patients >40 years undergoing abdominal CT/MRI. Evidence of subclinical autonomous glucocorticoid hypersecretion (SAGH) is found in 5–10% of cases depending on the diagnostic criteria/thresholds adopted.Aim: To examine the utility of basal DHEAS measurement in the detection of SAGH in a cohort of patients with AI.Methods: Ninety-six consecutive subjects...

ea0021p204 | Endocrine tumours and neoplasia | SFEBES2009

Temozolomide-induced regression of hepatic metastases in a pituitary corticotroph carcinoma with low O6-methylguanine-DNA methyltransferase expression

Burton Hannah , Annamalai Anand K , Dean Andrew , Kovacs Kalman , Antoun Nagui , Kirollos Ramez W , Simpson Helen L , Jeffries Sarah J , Burnet Neil G , Gurnell Mark

Background: Pituitary carcinoma occurs in ~0.2% of resected pituitary tumours, and carries a poor prognosis (mean survival <4 years), with standard chemotherapeutic regimens showing limited efficacy. However, recent evidence suggests that temozolomide, an orally active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas. Low levels of expression of the DNA-repair enzyme ...